PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
|
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
  • [1] PEG-IFN alfa-2a (40KD) (PEGASYS®) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC).
    Ideo, G
    Antonucci, G
    Attili, AF
    Babudieri, S
    Chirianni, A
    Craxì, A
    Di Perri, G
    Francavilla, A
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Tripi, S
    Sarracino, M
    HEPATOLOGY, 2003, 38 (04) : 728A - 728A
  • [2] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)
    Ideo, G
    Attili, A
    Ruggiero, G
    Craxi, A
    Di Perri, G
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Suter, F
    Sarracino, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 146 - 146
  • [3] PEG-IFN alfa-2a (40KD) (Pegasys) plus ribavirin (RBV) vs IFN alfa-2a (Roferon-A) in naive patients with chronic hepatitis C (CHC) and genotype 1.
    Cariti, G
    Andreoni, M
    Calleri, G
    Manca, A
    Rosina, F
    Sartori, M
    Tabone, M
    Grasso, A
    Picciotto, A
    Smedile, A
    Rizzetto, M
    HEPATOLOGY, 2002, 36 (04) : 595A - 595A
  • [4] Peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
    Fargion, S
    Borzio, M
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 139 - 140
  • [5] A randomised controlled trial on pegylated interferon alfa-2a (40KD) (pegasys) or ifn alfa-2a (roferon-a) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naive patients with chronic HCV
    Mangia, A
    Ricci, GL
    Minerva, N
    Persico, M
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    di Festi, D
    Annese, M
    Guadagnino, V
    Spirito, F
    Andriulli, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 153 - 153
  • [6] Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) alfa-2a (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN alfa-2a (roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study
    Brillanti, S
    Mangia, A
    Cimino, L
    Civolani, A
    Fatuzzo, F
    Fenoglio, L
    Levrero, M
    Minoli, G
    Persico, M
    Rumi, MG
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 129
  • [7] End of treatment and sustained response to peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC).
    Fargion, S
    Borzio, M
    Cargnel, A
    HEPATOLOGY, 2003, 38 (04) : 733A - 733A
  • [8] Sustained virological response (SVR) to peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC
    Fargion, S
    Borzio, M
    Maraschi, A
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2004, 40 : 140 - 140
  • [9] Peginterferon alfa-2a (40KD) (Pegasys) plus ribanirin (RBV) and amantadine (AMA) vs induction therapy with interferon alf,-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC).
    Fargion, SR
    Borzio, M
    Cargnel, A
    HEPATOLOGY, 2002, 36 (04) : 572A - 572A
  • [10] Pegylated 40kDA IFN alfa-2a plus amantadine (AMA) or ribavirin (RBV) in naives with chronic hepatitis C (CHC): The HIMPCT (Hepatitis Italian Multicenter Pegasys Amantadine Cooperative Trial)
    Ideo, G
    Angelico, M
    Chirianni, A
    Craxi, A
    Di Perri, G
    Minoli, L
    Montalto, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Scalzini, A
    Sarracino, M
    JOURNAL OF HEPATOLOGY, 2002, 36 : 112 - 112
12345